Eton Pharmaceuticals, Inc. Income Statement
ETON|7 years of annual SEC 10-K data (FY2019-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 7 fiscal years. All figures from audited SEC 10-K filings.
Eton Pharmaceuticals, Inc. reported $32M in revenue and $936,000 in net loss for FY2025. Revenue has grown at a 99.6% compound annual rate over the past 6 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score 0.63 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $31.6M | $21.3M | $21.8M | $39.0K | $959.0K | $959.0K | $500.0K |
| Cost of Revenue | $10.6M | $6.9M | $2.8M | $436.0K | - | $453.0K | $453.0K |
| Gross Profit | $21.1M | $14.3M | $19.0M | -$397.0K | $506.0K | $506.0K | $506.0K |
| SG&A Expense | $18.9M | $18.6M | $14.3M | $12.6M | $7.6M | $4.7M | $3.2M |
| R&D Expense | $3.3M | $4.0M | $6.2M | $14.1M | $11.6M | $5.6M | $3.9M |
| Operating Income | -$1.2M | -$8.3M | -$1.5M | -$27.1M | -$18.6M | -$10.3M | -$7.2M |
| Interest Expense | $1.1M | $955.0K | $1.0M | $884.0K | $98.0K | $98.0K | - |
| Income Tax | $247.0K | $0 | $0 | - | - | - | - |
| Net Income | -$936.0K | -$9.0M | -$2.0M | -$28.0M | -$18.3M | -$12.7M | -$7.2M |
| EPS (Basic) | -$0.04 | -$0.36 | -$0.08 | -$1.33 | - | - | - |
| EPS (Diluted) | - | - | - | - | -$1.03 | -$5.80 | -$2.50 |
| Shares Outstanding | 25.7M | 25.4M | 24.3M | 24.6M | 24.3M | 17.9M | 17.6M |
| Gross Margin | 66.6% | 67.4% | 87.1% | -1018.0% | 52.8% | 52.8% | 101.2% |
| Operating Margin | -3.8% | -38.9% | -6.9% | -69515.4% | -1939.6% | -1076.2% | -1430.0% |
| Profit Margin | -3.0% | -42.4% | -8.9% | -71717.9% | -1910.3% | -1328.5% | -1431.2% |